Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27825329 | 0.88 | MMP2 (0.49) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL27907181 | 0.86 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19 | |
| SCHEMBL4385189 | 0.83 | CYP2C9 (0.51) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL9173697 | 0.79 | MAOA (0.47) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL9472324 | 0.78 | APOBEC3G (0.61) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL223717 | 0.78 | CHRNA7 (0.53) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL3484527 | 0.78 | CHRNA7 (0.53) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL29582043 | 0.78 | CHRNA7 (0.53) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL1786728 | 0.78 | CHRNA7 (0.53) | CHRNA7SLC6A4SLC6A2SLC6A3CYP2C9 | |
| SCHEMBL15357914 | 0.77 | PDE7A (0.50) | CHRNA7SLC6A4SLC6A2SLC6A3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0396827-A1 | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1990-11-14 | — | — | EP | claimed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | disclosed |
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007036781-A1 | DIPHENYL ETHER MONOAMINE REUPTAKE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| US-6410736-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001027068-A1 | BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0396827-A1 | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1990-11-14 | — | — | EP | disclosed |
| EP-0396827-A1 | 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1990-11-14 | — | — | EP | disclosed |
| US-4055665-A | Treating arrythmia with phenylthioaralkylamines | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4055665-A | Treating arrythmia with phenylthioaralkylamines | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4018830-A | Phenylthioaralkylamines | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4018830-A | Phenylthioaralkylamines | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | AZI2, NOD1, AADAC | CHRNA7 4657/4885SLC6A4 3315/4885SLC6A2 3023/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | CHRNA7 321/4885SLC6A4 150/4885SLC6A2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.